EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte Studie

Mifepristone and misoprostol versus placebo and misoprostol for resolution of miscarriage in women diagnosed with missed miscarriage: the MifeMiso RCT

Adam Devall iD, Justin Chu iD, Leanne Beeson iD, Pollyanna Hardy iD, Versha Cheed iD, Yongzhong Sun iD, Tracy Roberts iD, Chidubem Okeke Ogwulu iD, Eleanor Williams iD, Laura Jones iD, Jenny La Fontaine Papadopoulos iD, Ruth Bender-Atik iD und 28 weitere

Health Technology Assessment · 2021-11 · 25 (68) · 1-114

DOI: 10.3310/hta25680 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Health Technology Assessment, 2021-11. Verfasst von Adam Devall und 39 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. Hauptthemen laut MEDLINE: Abortion, Spontaneous, Misoprostol. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 129 Literaturangaben. Gefördert von: Department of Health, Health Technology Assessment programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Trial design A randomised, parallel-group, double-blind, placebo-controlled multicentre study with health economic and nested qualitative studies to determine if mifepristone (Mifegyne ® , Exelgyn, Paris, France) plus misoprostol is superior to misoprostol alone for the resolution of missed miscarriage.

Methods

Women diagnosed with missed miscarriage in the first 14 weeks of pregnancy were randomly assigned (1 : 1 ratio) to receive 200 mg of oral mifepristone or matched placebo, followed by 800 μg of misoprostol 2 days later. A web-based randomisation system allocated the women to the two groups, with minimisation for age, body mass index, parity, gestational age, amount of bleeding and randomising centre. The primary outcome was failure to pass the gestational sac within 7 days after randomisation. The prespecified key secondary outcome was requirement for surgery to resolve the miscarriage. A within-trial cost-effectiveness study and a nested qualitative study were also conducted. Women who completed the trial protocol were purposively approached to take part in an interview to explore their satisfaction with and the acceptability of medical management of missed miscarriage.

Results

A total of 711 women, from 28 hospitals in the UK, were randomised to receive either mifepristone plus misoprostol (357 women) or placebo plus misoprostol (354 women). The follow-up rate for the primary outcome was 98% (696 out of 711 women). The risk of failure to pass the gestational sac within 7 days was 17% (59 out of 348 women) in the mifepristone plus misoprostol group, compared with 24% (82 out of 348 women) in the placebo plus misoprostol group (risk ratio 0.73, 95% confidence interval 0.54 to 0.98; p = 0.04). Surgical intervention to resolve the miscarriage was needed in 17% (62 out of 355 women) in the mifepristone plus misoprostol group, compared with 25% (87 out of 353 women) in the placebo plus misoprostol group (risk ratio 0.70, 95% confidence interval 0.52 to 0.94; p = 0.02). There was no evidence of a difference in the incidence of adverse events between the two groups. A total of 42 women, 19 in the mifepristone plus misoprostol group and 23 in the placebo plus misoprostol group, took part in an interview. Women appeared to have a preference for active management of their miscarriage. Overall, when women experienced care that supported their psychological well-being throughout the care pathway, and information was delivered in a skilled and sensitive manner such that women felt informed and in control, they were more likely to express satisfaction with medical management. The use of mifepristone and misoprostol showed an absolute effect difference of 6.6% (95% confidence interval 0.7% to 12.5%). The average cost per woman was lower in the mifepristone plus misoprostol group, with a cost saving of £182 (95% confidence interval £26 to £338). Therefore, the use of mifepristone and misoprostol for the medical management of a missed miscarriage dominated the use of misoprostol alone.

Limitations

The results from this trial are not generalisable to women diagnosed with incomplete miscarriage and the study does not allow for a comparison with expectant or surgical management of miscarriage. Future work Future work should use existing data to assess and rank the relative clinical effectiveness and safety profiles for all methods of management of miscarriage.

Conclusions

Our trial showed that pre-treatment with mifepristone followed by misoprostol resulted in a higher rate of resolution of missed miscarriage than misoprostol treatment alone. Women were largely satisfied with medical management of missed miscarriage and would choose it again. The mifepristone and misoprostol intervention was shown to be cost-effective in comparison to misoprostol alone.

Trial registration

Current Controlled Trials ISRCTN17405024. Funding This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment ; Vol. 25, No. 68. See the NIHR Journals Library website for further project information.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Abortion, SpontaneousMisoprostolCost-Benefit AnalysisFemaleHumansMifepristonePregnancyTechnology Assessment, Biomedical

Stichwörter der Autor:innen

GESTATIONAL SACMEDICAL MANAGEMENTMIFEPRISTONEMISOPROSTOLMISSED MISCARRIAGEPREGNANCYRANDOMISED CONTROLLED TRIAL

Substanzen

MisoprostolMifepristone

Autor:innen und Institutionen

  • Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
  • Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
  • National Perinatal Epidemiology Unit Clinical Trials Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
  • Miscarriage Association, Wakefield, UK.
  • Tommy's Charity, London, UK.
  • Sunderland Royal Hospital, South Tyneside & Sunderland NHS Foundation Trust, Sunderland, UK.

ORCID-Profile: Adam Devall, Justin Chu, Leanne Beeson, Pollyanna Hardy, Versha Cheed, Yongzhong Sun, Tracy Roberts, Chidubem Okeke Ogwulu, Eleanor Williams, Laura Jones, Jenny La Fontaine Papadopoulos, Ruth Bender-Atik, Jane Brewin, Kim Hinshaw, Meenakshi Choudhary, Amna Ahmed, Joel Naftalin, Natalie Nunes, Abigail Oliver, Feras Izzat, Kalsang Bhatia, Ismail Hassan, Yadava Jeve, Judith Hamilton, Shilpa Deb, Cecilia Bottomley, Jackie Ross, Linda Watkins, Martyn Underwood, Ying Cheong, Pratima Gupta, Rachel Small, Stewart Pringle, Frances Hodge, Anupama Shahid, Ioannis Gallos, Andrew Horne, Siobhan Quenby, Arri Coomarasamy

Förderung

  • Department of Health
  • Health Technology Assessment programme

Zitieren

APA

Devall, A., Chu, J., Beeson, L., Hardy, P., Cheed, V., Sun, Y., Roberts, T., Ogwulu, C. O., Williams, E., Jones, L., Papadopoulos, J. F., Bender-Atik, R., Brewin, J., Hinshaw, K., Choudhary, M., Ahmed, A., Naftalin, J., Nunes, N., Oliver, A., …, & Coomarasamy, A. (2021). Mifepristone and misoprostol versus placebo and misoprostol for resolution of miscarriage in women diagnosed with missed miscarriage: the MifeMiso RCT. Health Technology Assessment, 25(68), 1-114. https://doi.org/10.3310/hta25680

Vancouver

Devall A, Chu J, Beeson L, Hardy P, Cheed V, Sun Y, et al. Mifepristone and misoprostol versus placebo and misoprostol for resolution of miscarriage in women diagnosed with missed miscarriage: the MifeMiso RCT. Health Technology Assessment. 2021;25(68):1-114. doi:10.3310/hta25680

BibTeX
@article{Devall2021,
  author = {Devall, Adam and Chu, Justin and Beeson, Leanne and Hardy, Pollyanna and Cheed, Versha and Sun, Yongzhong and Roberts, Tracy and Ogwulu, Chidubem Okeke and Williams, Eleanor and Jones, Laura and Papadopoulos, Jenny La Fontaine and Bender-Atik, Ruth and Brewin, Jane and Hinshaw, Kim and Choudhary, Meenakshi and Ahmed, Amna and Naftalin, Joel and Nunes, Natalie and Oliver, Abigail and Izzat, Feras and Bhatia, Kalsang and Hassan, Ismail and Jeve, Yadava and Hamilton, Judith and Deb, Shilpa and Bottomley, Cecilia and Ross, Jackie and Watkins, Linda and Underwood, Martyn and Cheong, Ying and Kumar, Chitra and Gupta, Pratima and Small, Rachel and Pringle, Stewart and Hodge, Frances and Shahid, Anupama and Gallos, Ioannis and Horne, Andrew and Quenby, Siobhan and Coomarasamy, Arri},
  title = {Mifepristone and misoprostol versus placebo and misoprostol for resolution of miscarriage in women diagnosed with missed miscarriage: the MifeMiso RCT},
  journal = {Health Technology Assessment},
  year = {2021},
  volume = {25},
  number = {68},
  pages = {1--114},
  doi = {10.3310/hta25680}
}
Kostenlos starten →